Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors

1976 • 1,617 citations

Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors

2016 • 1,466 citations

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 • 1,225 citations

Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors

1976 • 978 citations

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.

1999 • 217 citations

BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)

1999 • 189 citations

Suppression of Murine Tumor Growth by Immune Reaction to the Bacillus Calmette-Guérin Strain of <italic>Mycobacterium bovis</italic>

1972 • 102 citations

What Is the Optimal Regimen for BCG Intravesical Therapy?

2000 • 98 citations

RECURRENCE, PROGRESSION AND SUCCESS IN STAGE TA GRADE 3 BLADDER TUMORS TREATED WITH LOW DOSE BACILLUS CALMETTE-GUERIN INSTILLATIONS

2000 • 95 citations

Dose-Response of Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Cancer

1992 • 89 citations

LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTS

2000 • 83 citations

Low-Dose BCG Instillations in the Treatment of Stage T1 Grade 3 Bladder Tumours: Recurrence, Progression and Success

1998 • 72 citations

Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy

1996 • 55 citations

Improving the Safety of BCG Immunotherapy by Dose Reduction

1995 • 49 citations

Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ.

2002 • 43 citations

Modified Induction Course: A Solution to Side-Effects?

2000 • 43 citations

Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer

1995 • 33 citations

BCG’s Mechanism of Action – Increasing our Understanding

2000 • 29 citations

Low‐dose bacille Calmette‐Guerin (BCG) therapy in superficial high‐risk bladder cancer: a phase II study with the BCG strain Connaught Canada

1995 • 26 citations

Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.

1989 • 14 citations

Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results.

1989 • 11 citations

LOW DOSE vs STANDARD DOSE BCG THERAPY OF SUPERFICIAL BLADDER CANCER

1999 • 9 citations

Nuestra experiencia con instilaciones de 1 mg de vacuna bcg en cáncer vesical etapa t1

1999 • 9 citations

[Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].

1996 • 3 citations

Prostate-Specific Membrane Antigen in the Diagnosis of Prostatic Carcinoma

1995 • 2 citations

Complicaciones del tratamiento endovesical con BCG en una serie de doscientos pacientes

1999 • 1 citations